Version 1
: Received: 10 July 2024 / Approved: 10 July 2024 / Online: 10 July 2024 (12:42:53 CEST)
How to cite:
Jonny, J.; Sitepu, E. C.; Lister, I. N. E.; Chiuman, L.; Putranto, T. A. The Potential of DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus. Preprints2024, 2024070862. https://doi.org/10.20944/preprints202407.0862.v1
Jonny, J.; Sitepu, E. C.; Lister, I. N. E.; Chiuman, L.; Putranto, T. A. The Potential of DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus. Preprints 2024, 2024070862. https://doi.org/10.20944/preprints202407.0862.v1
Jonny, J.; Sitepu, E. C.; Lister, I. N. E.; Chiuman, L.; Putranto, T. A. The Potential of DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus. Preprints2024, 2024070862. https://doi.org/10.20944/preprints202407.0862.v1
APA Style
Jonny, J., Sitepu, E. C., Lister, I. N. E., Chiuman, L., & Putranto, T. A. (2024). The Potential of DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus. Preprints. https://doi.org/10.20944/preprints202407.0862.v1
Chicago/Turabian Style
Jonny, J., Linda Chiuman and Terawan Agus Putranto. 2024 "The Potential of DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus" Preprints. https://doi.org/10.20944/preprints202407.0862.v1
Abstract
Diabetic Kidney Disease (DKD) is a common complication of Type 2 Diabetes Mellitus and a major risk factor for end-stage kidney disease. The immune system plays a significant role in the pathogenesis of DKD, involving infiltration of immune cells in the kidney, upregulation of in-flammatory mediators, downregulation of anti-inflammatory mediators, and disturbance in ad-hesion molecules and growth factors. Dendritic cells are professional antigen-presenting cells acting as a bridge connecting innate and adaptive immune responses. DC is also capable of modulating inflammation. Autologous dendritic cells can be made by in vitro differentiation of peripheral blood monocytes and then utilized as a cell-based therapy. Cell-based therapy for DKD is currently focused on utilizing the anti-inflammatory properties of stem cells. However, research suggests unsatisfactory results due to several limitations. This article highlights the possibility of using DC as a cell-based therapy for DKD through its role in controlling inflammation.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
